Australia's most trusted
source of pharma news
Saturday, 15 March 2025
Posted 12 March 2025 PM
Gilead has garnered such strong results from Phase 1 trials of two new formulations of a pre-exposure prophylaxis (PrEP) antiviral targeting HIV, that it will leap straight to Phase 3 trials this year.
The Phase 1 trial was for two formulations of a once-yearly intramuscular injection of lenacapavir. Gilead said the injections "achieved and maintained plasma concentrations exceeding those associated with HIV prevention efficacy".
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.